Smoking cessation 2008.
Wonnacott
Susan
S
University of Bath, Department of Biology & Biochemistry, Bath, BA2 7AY, UK. bsssw@bath.ac.uk
D001552:Benzazepines / Q000009:adverse effects / Q000627:therapeutic use; D063387:Cannabinoid Receptor Antagonists; D011307:Drug Prescriptions; D006801:Humans; D008389:Marketing of Health Services; D009538:Nicotine / Q000037:antagonists & inhibitors / Q000276:immunology; D018722:Nicotinic Agonists / Q000276:immunology; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use; D011810:Quinoxalines / Q000009:adverse effects / Q000627:therapeutic use; D000077285:Rimonabant; D012907:Smoking / Q000276:immunology; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention; D014612:Vaccines / Q000627:therapeutic use; D000068580:Varenicline
D001552:Benzazepines; D063387:Cannabinoid Receptor Antagonists; D018722:Nicotinic Agonists; D010880:Piperidines; D011720:Pyrazoles; D011810:Quinoxalines; D014612:Vaccines; D009538:Nicotine; D000077285:Rimonabant; D000068580:Varenicline